Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805660 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
A Phase 1 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT02805660 is a Phase 1 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 83 participants.
The verdict
NCT02805660, a Phase 1 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor. This study is evaluating the combination regimen of mocetinostat and durvalumab in participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.
Interventions
- DRUG Mocetinostat - 50 mg
- DRUG Mocetinostat - 70 mg
- DRUG Mocetinostat - 90 mg
- DRUG Mocetinostat - Recommended Phase 2 Dose (70 mg)
- DRUG Durvalumab - 1500 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02805660
The ClinicalTrials.gov registry entry for NCT02805660 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Mocetinostat - 50 mg is the first listed.
NCT02805660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02805660 about?
NCT02805660 is a clinical study titled "Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC". Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor. This study is evaluating the combination regimen of mocetin...
What is the current status of trial NCT02805660?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2016-06-01. Estimated completion is 2019-12-20.
What interventions are being tested in trial NCT02805660?
The interventions under investigation include: Mocetinostat - 50 mg (DRUG), Mocetinostat - 70 mg (DRUG), Mocetinostat - 90 mg (DRUG), Mocetinostat - Recommended Phase 2 Dose (70 mg) (DRUG), Durvalumab - 1500 mg (DRUG).
Who is sponsoring clinical trial NCT02805660?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.